Principal Securities, Inc. Iovance Biotherapeutics, Inc. Transaction History
Principal Securities, Inc.
- $4.14 Trillion
- Q3 2024
Shares
3 transactions
Others Institutions Holding IOVA
# of Institutions
317Shares Held
240MCall Options Held
1.27MPut Options Held
1.68M-
Vanguard Group Inc Valley Forge, PA26MShares$319 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY25.9MShares$318 Million6.02% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$295 Million28.39% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$261 Million0.0% of portfolio
-
State Street Corp Boston, MA12.6MShares$155 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.94B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...